How many clinical trials are tracked of MESNA?

38 trials are tracked, 0 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Dermatology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

MESNA

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of MESNA

38 trials tracked of MESNA: 2 in phase 3 or 4.

38Trials tracked

2Phase 3 & 4

0Recruiting

0With published results

Phase distribution

Phase 4 1 Phase 3 1 Phase 2 29 Phase 1 3 Other / NA 4

Phase 4 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed
Phase 3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Completed
Phase 2 Off-the-shelf NK Cells + SCT for Myeloid Malignancies Completed
Phase 2 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Completed
Phase 2 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer Completed
Phase 2 Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas Completed

Show 32 more trials

Phase 2 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Completed
Phase 2 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Completed
Phase 2 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma Completed
Phase 2 RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia Completed
Phase 2 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed
Phase 2 Study of Bortezomib in Combination With Cyclophosphamide and Rituximab Completed
Phase 2 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Completed
Phase 2 Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Completed
Phase 2 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma Completed
Phase 2 Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia Completed
Phase 2 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed
Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
Phase 2 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed
Phase 2 High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors Completed
Phase 2 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Completed
Phase 2 Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia Completed
Phase 2 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Completed
Phase 2 Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Completed
Phase 2 Hematopoietic Stem Cell Transplant in Devic's Disease Completed
Phase 2 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Completed
Phase 2 Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Completed
Phase 2 Randomized Double Cord Blood Transplant Study Completed
Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Completed
Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
Phase 2 Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Completed
Phase 1 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Completed
Phase 1 A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed
Phase 1 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma Completed
N/A Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor Completed
N/A Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI) Completed
N/A Fosaprepitant in Patients Receiving Ifosfamide-based Regimen Completed
N/A TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.